<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225173</url>
  </required_header>
  <id_info>
    <org_study_id>G6HD</org_study_id>
    <secondary_id>NIH/CA56060</secondary_id>
    <nct_id>NCT00225173</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease</brief_title>
  <official_title>A Phase II Trial of Stanford VI ± Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease With 3+ Risk Factors: the G6 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant
      anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine
      and vinorelbine. The introduction of these new agents with their different mechanisms of
      action into the Stanford V regimen may increase effectiveness while maintaining a favorable
      toxicity profile with respect to fertility and a low risk of secondary leukemia. On this
      basis, we propose a new regimen, Stanford VI, for patients with bulky and advanced HD with 3
      or more risk factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive chemotherapy weekly for 19 weeks, alone or followed by irradiation as
      indicated per protocol guidelines.

        -  Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11

        -  Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11

        -  Cyclophosphamide 750 mg/m2 IV w 1, 5, 9

        -  Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11

        -  Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)

        -  Bleomycin 5 u/m2 IV w 2,4,6,8,10,12

        -  Gemcitabine 1250 mg/m2 IV w 13,15,17,19

        -  Vinorelbine 25 mg/m2 IV w 13,15,17,19

        -  Prednisone 40 mg/m2 PO qod w 1-10, taper
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from progression</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
Gemcitabine 1250 mg/m2 IV w 13,15,17,19
Vinorelbine 25 mg/m2 IV w 13,15,17,19
Prednisone 40 mg/m2 PO qod w 1-10, taper</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>hydroxydaunomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Alkaban-AQ</other_name>
    <other_name>Velban</other_name>
    <other_name>Vinblastine sulfate</other_name>
    <other_name>Vincaleukoblastine</other_name>
    <other_name>VLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m2 IV w 1, 5, 9</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Etopophos</other_name>
    <other_name>Toposar</other_name>
    <other_name>VePesid</other_name>
    <other_name>etoposide phosphate</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin</other_name>
    <other_name>leurocristine</other_name>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>Bleomycin 5 u/m2 IV w 2,4,6,8,10,12</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Blenoxane</other_name>
    <other_name>bleomycin sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1250 mg/m2 IV w 13,15,17,19</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Gemcitabine HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine 25 mg/m2 IV w 13,15,17,19</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>Vinorelbine tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 40 mg/m2 PO qod w 1-10, taper</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Liquid Pred</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated, locally extensive or advanced stage classical Hodgkin's disease

          -  3 or more adverse risk factors

          -  Age &gt; 18 years and &lt; 70 years.

          -  No prior invasive malignancies for &gt; 5 years except curatively-treated basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

          -  ECOG performance status 0 to 2

          -  WBC &gt; 4000/µL

          -  Platelets &gt; 100,000/µL

          -  Creatinine &lt; 2.0mg/dL

          -  Bilirubin &lt; 5.0mg/dL

        Exclusion Criteria:

          -  HIV-positive

          -  Pregnant or currently breast feeding women

          -  Lymphocyte predominant Hodgkin's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra J. Horning, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nodular sclerosis</keyword>
  <keyword>lymphocyte rich</keyword>
  <keyword>lymphocyte depleted</keyword>
  <keyword>mixed cellularity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

